Core Points - TTAM Research Institute has acquired the Personal Genome Service and Research Services business lines of 23andMe Holding Co. under Section 363 of the U.S. Bankruptcy Code [1] - 23andMe will continue to operate under TTAM, providing personalized DNA testing and research services while ensuring customer choice and data transparency [2] Company Information - 23andMe is a genetics-led consumer healthcare company focused on empowering a healthier future [6] - TTAM Research Institute is a nonprofit medical research organization dedicated to advancing understanding of DNA and enabling individuals to contribute their genetic information to scientific research [7]

Core Insights - Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, which includes its personal genome service, total health, research services, and biobank of genetic samples [1] - 23andMe will continue to provide consumer genome services post-acquisition [1] Group 1: Acquisition Details - The acquisition aims to enhance 23andMe's mission of helping individuals understand their DNA and improve personal health, while also supporting Regeneron's genetic research initiatives [2] - The deal is expected to close in the third quarter of this year, with Regeneron required to adhere to 23andMe's privacy policies regarding customer data [3] Group 2: Company Background - 23andMe filed for Chapter 11 bankruptcy protection in March, leading to the immediate resignation of CEO Anne Wojcicki [4] - The company, which went public in 2021 with a valuation of $6 billion, has struggled to achieve profitability and faced significant challenges, including a $30 million settlement for a data breach and substantial layoffs [5] - As of November, 23andMe reported debts of $2.3 billion and approximately $126 million in cash and cash equivalents, indicating a need for additional liquidity [5]

Core Viewpoint - 23andMe has entered into a definitive agreement to sell itself to Regeneron Pharmaceuticals for $256 million, ensuring compliance with privacy policies and consumer data protection [2][3][5]. Group 1: Transaction Details - The sale includes the acquisition of substantially all assets of 23andMe, specifically the Personal Genome Service (PGS) and Total Health and Research Services business lines, while excluding the Lemonaid Health subsidiary [3]. - The transaction is subject to court approval and is expected to close in the third quarter of 2025, following a court hearing scheduled for June 17, 2025 [5]. - The auction for the sale was completed on May 16, 2025, as part of 23andMe's Chapter 11 proceedings [5]. Group 2: Privacy and Compliance - Regeneron has committed to adhere to 23andMe's privacy policies and applicable laws, ensuring that customer personal data will be processed in accordance with existing consents and security measures [2][4]. - An independent Consumer Privacy Ombudsman will review the transaction's impact on consumer privacy and report to the court by June 10, 2025 [4]. Group 3: Company Statements - Mark Jensen, Chair of 23andMe's Board, expressed satisfaction with the transaction, highlighting its potential to maximize business value while protecting customer privacy [3]. - George D. Yancopoulos from Regeneron emphasized the company's commitment to safeguarding genetic data and enhancing 23andMe's mission to help individuals understand their DNA [4].